声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。11月13日,歌礼制药发布公告,每月一次的新一代胰淀素受体激动剂ASC36和新一代GLP-1R/GIPR双靶点激动剂ASC35复方制剂已进入临床开发阶段,预计2026年第二季度向美国FDA递交用于治疗肥胖症的新药临床试验申请。分析人士指出,ASC36与...
Source Link声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。11月13日,歌礼制药发布公告,每月一次的新一代胰淀素受体激动剂ASC36和新一代GLP-1R/GIPR双靶点激动剂ASC35复方制剂已进入临床开发阶段,预计2026年第二季度向美国FDA递交用于治疗肥胖症的新药临床试验申请。分析人士指出,ASC36与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.